Recent studies revealed some biomarkers including IL-18, CXCL9, neopterin and soluble tumor necrosis factor receptor type II might be useful for the prediction of the development of MAS and the diagnosis of the transition from active phase of s-JIA to MAS [14–21]. This evidence concerns the gene IL18 and macrophage activation syndrome.